Vaxcyte
PCVX
55.39
-2.97
-5.09%
Vaxcyte
US · PCVX
#1630 by market cap
Listed 2020
55.39
-2.97
-5.09%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions increased by 21 in the most recent period (2026/Q3).
- Total institutional ownership fell 4.2 percentage points.
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 112.85% -4.23pp
- Institutions
- 434 +21
- As of
- 2026/Q3 vs. prior period
Holder types
Mutual Fund84.82%
Hedge Fund11.79%
VC/PE Fund11.58%
Public Company2.32%
Sovereign Wealth Fund0.79%
Individual/Insider0.59%
Government Pension Fund0.54%
Private Company0.52%
Insurance Company0.26%
Top holders as of 2026-10-31
T. Rowe Price Group, Inc.
13.35% · 21.13M sh
FMR
13.17% · 20.85M sh
Janus Henderson Group plc
11.40% · 18.04M sh
BlackRock
7.69% · 12.18M sh
RA Capital Management, L.P.
7.25% · 11.47M sh
Wellington Management Group
4.42% · 7.00M sh
Vanguard Capital Management, LLC
4.15% · 6.57M sh
Vanguard Portfolio Management, LLC
4.15% · 6.57M sh
State Street Global Advisors
3.31% · 5.23M sh
Deep Track Capital, LP
2.72% · 4.30M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 16 buys · 33 sells
| Name | Role | Stake |
|---|---|---|
| Grant Pickering | Chief Executive Officer | 0.36% |
| James Wassil | Executive VP, Chief Scientific Officer & COO | 0.09% |
| Andrew Guggenhime | President | 0.07% |
| Harpreet Dhaliwal | -- | 0.01% |
| Heath Lukatch | Former Independent Director | 0.01% |
| Elvia Cowan | Senior VP of Finance & Chief Accounting Officer | 0.01% |
| Carlos Paya | Independent Chairperson | 0.01% |
| Teri Loxam | Independent Director | 0.01% |
| Halley Gilbert | Independent Director | 0.01% |
| Annie Drapeau | Independent Director | 0.01% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-11-10 | Harpreet Dhaliwal | -- | Derivative Exercise and Sale | -17,000 | $24.79–68.82 |
| 2026-11-01 | James Wassil | Executive VP, Chief Scientific Officer & COO | Derivative Exercise and Sale | -2,250 | $5.35–61.57 |
| 2026-11-01 | Elvia Cowan | Senior VP of Finance & Chief Accounting Officer | Derivative Exercise and Sale | -3,000 | $25.92–61.55 |
| 2026-10-04 | James Wassil | Chief Operating Officer | Intent to Sell (Form 144) | -18,000 | $86.74 |
| 2026-10-04 | James Wassil | Executive VP, Chief Scientific Officer & COO | Derivative Exercise and Sale | -18,000 | $5.35–86.74 |
| 2026-10-04 | Elvia Cowan | Senior VP of Finance & Principal Accounting Officer | Intent to Sell (Form 144) | -19,000 | $86.74 |
| 2026-10-04 | Elvia Cowan | Senior VP of Finance & Chief Accounting Officer | Derivative Exercise and Sale | -19,000 | $25.92–86.74 |
| 2026-09-30 | James Wassil | Executive VP, Chief Scientific Officer & COO | Derivative Exercise and Sale | -2,250 | $5.35–57.09 |
| 2026-09-08 | James Wassil | Executive VP, Chief Scientific Officer & COO | Automatic Disposition | -2,715 | $59.52–61.16 |
| 2026-09-08 | James Wassil | Executive VP, Chief Scientific Officer & COO | Intent to Sell (Form 144) | -1,334 | $59.99 |
| 2026-09-07 | Andrew Guggenhime | President | Sale to Issuer | -7,155 | $60.36 |
| 2026-09-07 | Grant Pickering | Chief Executive Officer | Sale to Issuer | -17,056 | $60.36 |
| 2026-09-07 | James Wassil | Executive VP, Chief Scientific Officer & COO | Sale to Issuer | -5,459 | $60.36 |
| 2026-09-07 | Elvia Cowan | Senior VP of Finance & Chief Accounting Officer | Sale to Issuer | -1,327 | $60.36 |
| 2026-09-07 | Harpreet Dhaliwal | -- | Sale to Issuer | -7,651 | $60.36 |
| 2026-09-03 | James Wassil | Executive VP, Chief Scientific Officer & COO | Intent to Sell (Form 144) | -1,381 | $59.73 |
| 2026-09-03 | Luis Jodar | Chief Medical Officer | Other Acquisition | +52,632 | -- |
| 2026-09-03 | Luis Jodar | Chief Medical Officer | Other Derivative Acquisition | +88,254 | $61.16 |
| 2026-09-01 | Andrew Guggenhime | President | Sale to Issuer | -2,705 | $60.74–61.58 |
| 2026-09-01 | Grant Pickering | Chief Executive Officer | Sale to Issuer | -6,289 | $60.74–61.58 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.
Vaxcyte discussion 0 comments